Scholar Rock is focused on discovering and developing drugs that selectively modulate growth factor activation in the disease microenvironment. Its lead clinical candidate, SRK-015, is a selective inhibitor of supracellular activation of myostatin being developed to improve muscle strength and motor function in patients with spinal muscular atrophy (SMA). The company plans to evaluate SRK-015 both in SMA patients on therapies that upregulate SMN protein and as monotherapy in certain subpopulations. Proceeds from the financing will be used to advance SRK-015 into clinical development in the first half of 2018. Scholar Rock also intends to use the funding to progress additional development candidates in fibrosis, immuno-oncology, and anemias associated with iron restriction. SRK-015 is investigational and has not been approved by the FDA or any other regulatory agency. Scholar Rock is a biotechnology company focused on discovering and developing biologic therapies that selectively target supracellular activation of growth factors in disease microenvironments. Its platform aims to modulate supracellular activation to achieve highly specific, localized efficacy at sites of disease while avoiding systemic inhibition. The company is developing a pipeline targeting fibrosis, muscle disease, immuno-oncology and autoimmune diseases. Scholar Rock's proprietary SRK-015 program targets muscle disease, and the company cites data from its partnership with Janssen. The firm was founded on discoveries by Professors Timothy Springer and Leonard Zon and is backed by investors including Polaris Partners, ARCH Venture Partners, EcoR1 Capital and The Kraft Group. It announced a $36 million Series B financing to advance its drug discovery and development efforts. Scholar Rock develops niche modulators, a novel class of biologic therapies that selectively modulate activation of growth factors in the disease microenvironment. Its core proprietary and partnered drug discovery programs target specific growth factors, including members of the TGF-beta superfamily. Those targets are implicated in fibrosis, diseases of the musculoskeletal system and autoimmune diseases. The company was founded by Professors Timothy Springer and Leonard Zon and is led by CEO and President Nagesh Mahanthappa. Scholar Rock raised $20M in a Series A and intends to use the funds to advance its preclinical niche modulators toward clinical drug development.

Total raised

$103M

Funding rounds

3

Latest round

Series C

Latest activity

Jan 2018